| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sergio Giralt | Q66764444 |
| P2093 | author name string | Paul Martin | |
| Mary Horowitz | |||
| Corey Cutler | |||
| Vincent T Ho | |||
| Robert Soiffer | |||
| Shelly Carter | |||
| James Ferrara | |||
| Roberta Adams | |||
| P433 | issue | 8 | |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 571-575 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation | |
| P478 | volume | 11 |
| Q34316427 | A case of transplantation-associated thrombotic microangiopathy with cardiac involvement successfully treated with plasma exchange |
| Q26992169 | A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury |
| Q33924570 | A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). |
| Q33573529 | A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation |
| Q36662042 | A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation |
| Q80479511 | ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy |
| Q33418088 | Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy |
| Q33408788 | Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy |
| Q34448474 | Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States |
| Q91713789 | Acute kidney injury in the patient with cancer |
| Q90184241 | Adverse Effects of Virus-Specific T-Cell Therapy: An Integrative Review |
| Q92600857 | Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions |
| Q35200663 | Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complications |
| Q50510634 | Apoptotic cells in peripheral blood and multiple organ injury. |
| Q38689056 | Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation |
| Q37174366 | BK viremia precedes hemorrhagic cystitis in children undergoing allogeneic hematopoietic stem cell transplantation |
| Q55431201 | Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature. |
| Q33388255 | Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation |
| Q26739894 | Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea |
| Q58553367 | Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT |
| Q80525543 | Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation |
| Q50622232 | Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. |
| Q57252632 | Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease |
| Q33386036 | Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning |
| Q42086661 | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea |
| Q64094847 | Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics |
| Q57456627 | Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD |
| Q88851226 | Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q50195063 | Delayed Development of Hemolytic Anemia with Fragmented Red Blood Cells and Cardiac and Renal Impairments after High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma |
| Q33375739 | Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? |
| Q33402385 | Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? |
| Q90317718 | EASIX and mortality after allogeneic stem cell transplantation |
| Q95567275 | Early and Acute Complications and the Principles of HSCT Nursing Care |
| Q33391308 | Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. |
| Q44696198 | Early coagulation disorder after allogeneic stem cell transplantation is a strong prognostic factor for transplantation-related mortality, and intervention with recombinant human thrombomodulin improves the outcome: a single-center experience. |
| Q52875784 | Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. |
| Q33412325 | Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. |
| Q91010169 | Effects of recombinant thrombomodulin on long-term prognosis after allogeneic hematopoietic stem cell transplantation |
| Q90450386 | Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic stem cell transplantation |
| Q33375004 | Evaluation and management of patients with thrombotic thrombocytopenic purpura |
| Q37376599 | Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. |
| Q33418635 | Fragmented Red Cell as a Possible Favorable Prognostic Marker of Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy. |
| Q38077918 | Glomerular diseases seen with cancer and chemotherapy: a narrative review |
| Q34122035 | Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis |
| Q33424902 | Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy |
| Q28069228 | Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment |
| Q41992358 | Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. |
| Q33417613 | Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options |
| Q81434702 | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy: defining a disorder |
| Q36117735 | High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses |
| Q33424204 | Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation |
| Q33391206 | How I treat patients with thrombotic thrombocytopenic purpura: 2010 |
| Q33816022 | IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation |
| Q58415027 | Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation |
| Q50977317 | Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra. |
| Q47307319 | In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation |
| Q89987658 | Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy |
| Q64990670 | Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. |
| Q38806679 | Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? |
| Q33574136 | Late effects of blood and marrow transplantation |
| Q33392923 | Late-onset intestinal perforation in the setting of posttransplantation microangiopathy: a case report |
| Q80034696 | Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient |
| Q95501406 | Mini-review of kidney disease following hematopoietic stem cell transplant |
| Q63815460 | Monocyte-predominant engraftment, cytokine levels and early transplant-related complications in pediatric hematopoietic stem cell recipients |
| Q36962653 | Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation |
| Q33432069 | New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q38382457 | Onco-nephrology: current concepts and future perspectives |
| Q96304256 | Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach |
| Q33417690 | Outcomes of plasma exchange in patients with transplant-associated thrombotic microangiopathy based on time of presentation since transplant |
| Q49988935 | Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP). |
| Q40096407 | Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation |
| Q33430697 | Post-bone marrow transplant thrombotic microangiopathy |
| Q33384578 | Posttransplant thrombotic microangiopathy: sensitivity of proposed new diagnostic criteria |
| Q38902112 | Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation. |
| Q92974261 | Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study |
| Q48337187 | Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention |
| Q33420131 | Pretransplant-corrected QT dispersion as a predictor of pericardial effusion after pediatric hematopoietic stem cell transplantation |
| Q83832642 | Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor |
| Q35800856 | Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease |
| Q26750995 | Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents |
| Q33433122 | Recombinant thrombomodulin for secondary thrombotic thrombocytopenic purpura |
| Q87858624 | Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia |
| Q34316381 | Remission of microangiopathy in transplanted thalassemic child |
| Q33407913 | Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q46788671 | Renal pathology in hematopoietic cell transplantation recipients |
| Q33256286 | Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. |
| Q53091032 | Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. |
| Q97557966 | Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT |
| Q33413498 | Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus |
| Q80813563 | Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura |
| Q35231368 | Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT. |
| Q92092550 | Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab |
| Q35184589 | Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation |
| Q35193740 | Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids |
| Q43228479 | Sirolimus for treatment of steroid-refractory acute graft-versus-host disease |
| Q36892442 | Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience |
| Q30253063 | Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1. |
| Q33392710 | Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation |
| Q33410467 | TMA: beware of complements |
| Q40486613 | Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. |
| Q33405793 | Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient |
| Q26740251 | The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation |
| Q33378414 | The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection |
| Q40295927 | The clinical role of procalcitonin in hematopoietic SCT. |
| Q33424153 | The potential role of HLA-DRB1*11 in the development and outcome of haematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q33376858 | The thrombotic microangiopathies. |
| Q38287610 | Therapeutic apheresis for patients with cancer |
| Q99604299 | Thrombotic Microangiopathy After Post-Transplantation Cyclophosphamide-Based GVHD Prophylaxis |
| Q26785826 | Thrombotic microangiopathy associated with proteasome inhibitors |
| Q33403897 | Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis |
| Q49375853 | Thrombotic microangiopathy following haematopoietic stem cell transplant |
| Q35098992 | Thrombotic microangiopathy in haematopoietic cell transplantation: an update |
| Q33383355 | Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment |
| Q48346280 | Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. |
| Q33372991 | Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab |
| Q33387767 | Thrombotic thrombocytopenic purpura: recognition and management |
| Q92798609 | Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal |
| Q64063450 | Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management |
| Q33395253 | Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus |
| Q38709053 | Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. |
| Q92087747 | Transplant-associated thrombotic microangiopathy: Diagnostic challenges and management strategies |
| Q54306708 | Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. |
| Q58561025 | Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? |
| Q30235311 | Transplant-associated thrombotic microangiopathy: opening Pandora's box. |
| Q33424311 | Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease |
| Q33393068 | Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease |
| Q33386308 | Transplantation-associated thrombotic microangiopathy: effect of concomitant GVHD on efficacy of therapeutic plasma exchange |
| Q33428744 | Treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin |
| Q53175337 | Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. |
| Q89095408 | Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy |
| Q33408395 | Using rheopheresis for stem cell transplantation-associated thrombotic microangiopathy (TA-TMA). |
| Q98772376 | Variable clinical manifestations of hematopoietic stem cell transplant-associated thrombotic microangiopathy |
| Q88251319 | [Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy: 16 cases report and literature review] |
Search more.